RETURN TO WORK SCREENING AND TESTING

LabCorp Employer Services (LES) is committed to helping America get back to work.

In response to the COVID-19 outbreak, LES is pleased to announce the launch of new end-to-end solutions for screening and testing services:

COVID-19 PCR Testing

The COVID-19 PCR test uses a self-collection nasal swab to detect the presence of the underlying virus that causes COVID-19. Staff will be available on-site to direct and observe sample collection and prepare for shipment.

COVID-19 Serological Testing

The COVID-19 Serological Antibody test determines the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19, and helps identify individuals who have been exposed to the virus. This test is available as a dried blood spot fingerstick test or as a blood draw, both of which can be performed conveniently at your location.

Stay at Work and Return to Work Process

This service helps essential businesses identify employees with an elevated temperature, and other possible COVID-19 symptoms, who are reporting to work during the COVID-19 outbreak or requesting to return to work. Both the Stay at Work and Return to Work services consist of a simple, two-step process:

- Completion of a questionnaire to screen for symptoms that may be consistent with COVID-19
- Performance of a non-invasive temperature check

Convenient off-site options:

At-Home PCR Testing:

We offer a COVID-19 test for at-home sample collection, which detects the presence of the virus that causes COVID-19 via a self-administered nasal swab, and can be sent directly to employees at their home. The at-home collection test kit has received Emergency Use Authorization from the U.S. Food and Drug Administration.

Off-Site Serology Testing:

The COVID-19 serological antibody test is a blood draw test, performed at a LabCorp patient service center, including LabCorp at Walgreens. A phlebotomist at the location will collect and prepare the sample.

Following each screening, employees will be cleared for work or directed to follow next steps, in accordance with the employer's COVID-19 policies.

LabCorp's COVID-19 PCR test has not been FDA cleared or approved, has been authorized by the FDA under an Emergency Use Authorization (EUA), and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LabCorp's fingerstick, or dried blood spot, IgG antibody test is being provided as a laboratory developed test, and uses the Euroimmun platform which received Emergency Use Authorization by the U.S. Food and Drug Administration. LabCorp completed independent validation studies on this testing. The COVID-19 IgG antibody blood test detects the presence of antibodies to the virus and can help determine if an individual may have been exposed to the virus. While antibody tests are helpful to understand if an individual has developed antibodies and a potential immune response, antibody testing should not be used as the sole basis to diagnose or exclude infection.

For more information, please visit **https://www.labcorp.com/coronavirus-disease-covid-19/employer-services**

LabCorp

www.LabCorp.com

All service offerings are conducted by trained LabCorp Employer Services staff.